Try our beta test site
111 studies found for:    myeloma and lenalidomide | Open Studies
Show Display Options
Rank Status Study
1 Recruiting Safety Study of Lenalidomide/Dexamethasone to Treat Patients With Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide;   Drug: Dexamethasone
2 Recruiting Sonidegib and Lenalidomide After Stem Cell Transplant in Treating Patients With Multiple Myeloma
Conditions: Recurrent Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide;   Drug: Sonidegib
3 Recruiting Safety And Efficacy Of Lenalidomide As Maintenance Therapy In Patients With Newly Diagnosed Multiple Myeloma Following A Tandem Autologous-Allogeneic Transplant
Condition: Multiple Myeloma
Intervention: Drug: Lenalidomide
4 Recruiting Trial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide;   Drug: Carfilzomib;   Drug: Dexamethasone
5 Recruiting Treatment Optimization in Patients With Untreated Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide;   Drug: Placebo
6 Recruiting Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Bortezomib;   Drug: Lenalidomide;   Drug: Dexamethasone
7 Recruiting A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: Vorinostat, Lenalidomide, Carfilzomib, Dexamethasone
8 Recruiting Lenalidomide Plus Melphalan as a Preparative Regimen for Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma: A Phase 1 / 2 Study
Condition: Multiple Myeloma
Interventions: Drug: lenalidomide;   Drug: melphalan
9 Recruiting Combination of Lenalidomide and Dexamethasone in Treatment of Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide, Dexamethasone;   Drug: Lenalidomide, Dexamethasone, PBSCT
10 Recruiting Lenalidomide Maintenance in Plasma Cell Myeloma
Condition: Plasma Cell Myeloma
Intervention: Drug: Lenalidomide
11 Recruiting Elotuzumab in Autologous Stem Cell Transplantation (ASCT) and Lenalidomide Maintenance for Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Elotuzumab;   Drug: Lenalidomide;   Other: autologous PBMC reconstitution;   Other: ASCT
12 Recruiting A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering Myeloma
Condition: Smoldering Multiple Myeloma
Interventions: Drug: Nivolumab;   Drug: Lenalidomide;   Drug: Dexamethasone
13 Recruiting Response Adapted Therapy With Bortezomib/Dexamethasone Followed by Addition of Lenalidomide in Non Responders as Initial Treatment for Patients With Multiple Myeloma
Condition: Multiple Myeloma (MM)
Interventions: Drug: Bortezomib;   Drug: Dexamethasone;   Drug: Lenalidomide
14 Recruiting Pembrolizumab + Lenalidomide Post Autologous Stem Cell Transplant (ASCT) in High-risk Multiple Myeloma (MM)
Condition: Multiple Myeloma
Interventions: Drug: Pembrolizumab;   Drug: Lenalidomide;   Drug: Dexamethasone
15 Recruiting Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Daratumumab;   Drug: Lenalidomide;   Drug: Dexamethasone
16 Recruiting A Study of JNJ-54767414 (Daratumumab) in Combination With Lenalidomide and Dexamethasone in Japanese Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-dose Therapy and Autologous Stem Cell Transplantation
Condition: Multiple Myeloma
Interventions: Drug: Daratumumab (16 mg/kg);   Drug: Lenalidomide;   Drug: Dexamethasone
17 Recruiting Cyclophosphamide With Biochemical Progression During Lenalidomide-Dexamethasone Treatment for Relapsed/Refractory Multiple Myeloma (MM)
Condition: Multiple Myeloma
Interventions: Drug: Cyclophosphamide;   Drug: Lenalidomide;   Drug: Dexamethasone
18 Recruiting Multicenter Clinical Trial to Investigate the Efficacy and Safety of Bendamustine, Dexamethasone and Thalidomide in Relapsed or Refractory Multiple Myeloma Patients After Treatment With Lenalidomide and Bortezomib or Which Are Ineligible to One of These Drugs
Condition: Multiple Myeloma
Intervention: Drug: Bendamustine + Dexamethasone + Thalidomide
19 Recruiting Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma
Conditions: Light Chain Deposition Disease;   Smoldering Plasma Cell Myeloma
Interventions: Other: Clinical Observation;   Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide;   Other: Quality-of-Life Assessment
20 Not yet recruiting Induction Therapy for Multiple Myeloma With Carfilzomib, Lenalidomide,Dexamethasone,Panobinostat
Condition: Multiple Myeloma
Interventions: Drug: Panobinostat;   Drug: Carfilzomib;   Drug: Lenalidomide;   Drug: Dexamethasone

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.